Lupin share price gains after partnering with Zydus for advanced diabetes and weight management therapy
News by Aliceblue News Desk
17 Mar 2026
Introduction
Leading pharmaceutical firms have entered a licensing agreement to co-market innovative Semaglutide Injection in India, enhancing patient access to advanced diabetes and weight management therapies.
Also Read: Tejas Networks shares extend rally, jump 8% on fresh 4G RAN deployment order in South Asia
Share price movement of Lupin
On March 17, 2026, Lupin Limited opened at ₹2,312.20, up 0.97% from its previous close of ₹2,290.15. The stock reached a high of ₹2,312.20 (0.97%) and a low of ₹2,285.50 (-0.20%). By 2:31 PM, it traded at ₹2,305.00, a 0.65% increase, with a market cap of ₹1,05,348.46 crore.
Lupin and Zydus Co-market Semaglutide
Lupin Limited has signed a Licensing and Supply Agreement with Zydus Lifesciences. The deal allows Lupin to co-market Semaglutide Injection in India under new brand names.
Lupin will market the injection as Semanext® and Livarise®. Zydus will continue selling it as SEMAGLYNTM, MASHEMATM, and ALTERMETM with a reusable pen device.
Lupin will pay Zydus upfront licensing fees and milestone-based payments. The partnership aims to enhance patient access to advanced diabetes and weight management therapies across India.
Stock performance of Lupin for period of 1 week, 6 months, and 1 year
Lupin Ltd delivered a 1-week return of -2.01%, a 6-month return of 11.9%, and a 1-year return of 15.0%.
Also Read: Dilip Buildcon: Stock in spotlight after winning lowest bid for ₹160 Cr Odisha road project
Shareholding pattern of Lupin
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 46.90% | 47% | 46.90% |
| FII | 21.50% | 20.50% | 21.30% |
| DII | 25.60% | 26.60% | 25.60% |
| Public | 6.00% | 6.10% | 6.30% |
About Lupin
Lupin Ltd (NSE: LUPIN) is a global pharmaceutical company from Mumbai, offering branded, generic, and biotech products across multiple therapy areas in over 100 markets worldwide.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Lupin Ltd share price rising today?
A: Lupin Ltd has signed a licensing agreement with Zydus Lifesciences to co-market Semaglutide Injection in India.
Q: What is Lupin Ltd’s main business focus?
A: Lupin Ltd focuses on branded and generic pharmaceuticals, biotechnology products, and active pharmaceutical ingredients across multiple therapy areas.
Q: What are the 52-week high and low of Lupin Ltd stock?
A: Lupin Ltd stock has a 52-week high of ₹2,376.00 and a 52-week low of ₹1,774.00.
News Author
Aliceblue News Desk
